Treatment schedule for BCR-ABL-positive ALL in the JALSG ALL202 study
Drug . | Dose . | Route . | Days . |
---|---|---|---|
Remission induction | |||
CPM | 1200 mg/m2* | 3 h IV | 1 |
DNR | 60 mg/m2† | 1 h IV | 1-3 |
VCR | 1.3 mg/m2‡ | IV | 1, 8, 15, 22 |
PSL | 60 mg/m2 | PO | 1-21§ |
Imatinib | 600 mg/d | PO | 8-63 |
MTX, AraC, Dex | 15, 40, 4 mg/d | IT | 29 |
Consolidation 1 (CI) | - | ||
MTX | 1 g/m2 | 24 h IV | 1 |
AraC | 2 g/m2∥ | 3 h IV | 2, 3 (12 hourly) |
MTX, AraC, Dex | 15, 40, 4 mg/d | IT | 1 |
Consolidation 2 (C2) | |||
Imatinib | 600 mg/d | PO | 1-28 |
MTX, AraC, Dex | 15, 40, 4 mg/d | IT | 1 |
Maintenance | |||
VCR | 1.3 mg/m2‡ | IV | 1 |
PSL | 60 mg/m2 | PO | 1-5 |
Imatinib | 600 mg/d | PO | 1-28 |
Drug . | Dose . | Route . | Days . |
---|---|---|---|
Remission induction | |||
CPM | 1200 mg/m2* | 3 h IV | 1 |
DNR | 60 mg/m2† | 1 h IV | 1-3 |
VCR | 1.3 mg/m2‡ | IV | 1, 8, 15, 22 |
PSL | 60 mg/m2 | PO | 1-21§ |
Imatinib | 600 mg/d | PO | 8-63 |
MTX, AraC, Dex | 15, 40, 4 mg/d | IT | 29 |
Consolidation 1 (CI) | - | ||
MTX | 1 g/m2 | 24 h IV | 1 |
AraC | 2 g/m2∥ | 3 h IV | 2, 3 (12 hourly) |
MTX, AraC, Dex | 15, 40, 4 mg/d | IT | 1 |
Consolidation 2 (C2) | |||
Imatinib | 600 mg/d | PO | 1-28 |
MTX, AraC, Dex | 15, 40, 4 mg/d | IT | 1 |
Maintenance | |||
VCR | 1.3 mg/m2‡ | IV | 1 |
PSL | 60 mg/m2 | PO | 1-5 |
Imatinib | 600 mg/d | PO | 1-28 |
C1 and C2 are alternatively repeated for 4 cycles. Maintenance is given every 4 weeks for 2 years from the date of CR.
CPM indicates cyclophosphamide; IV, intravenously; DNR, daunorubicin; VCR, vincristine; PSL, prednisolone; PO, per os; MTX, methotrexate; AraC, cytarabine; Dex, dexamethasone; and IT, intrathecally.
CPM 800 mg/m2 in case of patients aged 60 years or older.
DNR 30 mg/m2 in case of patients aged 60 years or older.
Max 2.0 mg in case of patients aged 60 years or older.
PSL for days 1 to 7 in case of patients aged 60 years or older.
AraC 1 g/m2 in case of patients aged 60 years or older.